Bladder cancer treatment has evolved significantly, offering patients a range of options from surgical removal to innovative therapies being tested in clinical trials, with the goal of controlling symptoms, preventing recurrence, and improving quality of life.

How Treatment Approaches Help Patients with Bladder Cancer

When someone receives a diagnosis of bladder cancer, treatment planning becomes a critical next step. The approach to treatment depends heavily on several factors, including how deeply the cancer has invaded the bladder wall, the grade of the tumor, the patient’s overall health, and personal preferences. The main goals of treatment can vary: some patients need therapy to destroy cancer cells confined to the bladder’s inner lining, while others require more aggressive approaches to tackle cancer that has spread into muscle tissue or beyond.^[1]

Bladder cancer is unique in that it has a strong tendency to come back even after successful treatment. About 75% of early-stage bladder cancers recur, which means that follow-up care and ongoing monitoring are just as important as the initial treatment itself.^[3] This characteristic shapes the entire treatment strategy, making surveillance an ongoing part of a patient’s journey.

Medical societies have established standard treatments that form the backbone of bladder cancer care. These are therapies with proven track records, backed by years of research and clinical experience. At the same time, scientists are actively exploring new therapeutic approaches through clinical trials. These investigational treatments aim to improve outcomes, reduce side effects, or offer options for patients whose cancer hasn’t responded to conventional therapies.^[10]

Standard Treatment Options for Bladder Cancer

The cornerstone of bladder cancer treatment is transurethral resection, a surgical procedure performed through the urethra without making an external incision. During this procedure, doctors use a special instrument called a cystoscope—a thin tube with a light and camera—to visualize the inside of the bladder. A small wire loop attached to the scope removes cancerous tissue or burns it away using high-energy electricity, a technique called fulguration. This approach serves multiple purposes: it confirms the diagnosis, determines how far the cancer has grown (staging), and provides the primary treatment for many early-stage tumors.^[8]

Following tumor removal, many patients receive additional therapy directly into the bladder, known as intravesical therapy. One of the most established treatments is Bacillus Calmette-Guérin (BCG), which became the first FDA-approved immunotherapy back in 1990. BCG consists of weakened live bacteria that trigger an immune response inside the bladder. When these bacteria are introduced, the immune system recognizes them as foreign invaders and mounts an attack—but in doing so, it also targets nearby bladder cancer cells. This treatment has proven remarkably effective for preventing cancer recurrence in patients with moderate- to high-grade disease, with approximately 70% of patients achieving remission.^[13]

Another option for intravesical treatment is chemotherapy, with mitomycin C being a commonly used drug. This medication is delivered as a liquid solution into the bladder, typically as a single dose right after tumor removal. For patients at lower risk of cancer progression, additional intravesical chemotherapy may be used instead of BCG. The medication works by killing cancer cells directly in the bladder lining, helping to prevent new tumors from forming.^[12]

When bladder cancer has invaded the muscle layer of the bladder wall—a situation called muscle-invasive bladder cancer—more aggressive treatment becomes necessary. The standard approach typically involves radical cystectomy, which means complete surgical removal of the bladder. In men, this surgery also removes the prostate and seminal vesicles; in women, it includes removal of the uterus, ovaries, and part of the vagina. Because the bladder is removed, surgeons must create a new way for the body to store and pass urine, a procedure called urinary diversion. This might involve redirecting urine into the colon, using catheters to drain a surgically created pouch, or creating an opening in the abdomen that connects to an external collection bag.^[10]

Before bladder removal surgery, many patients receive neoadjuvant chemotherapy—chemotherapy given before the main treatment. The most common regimen uses a combination of drugs including cisplatin, often paired with gemcitabine (abbreviated as GC) or in a combination called MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). The purpose of giving chemotherapy first is to shrink the tumor, making surgery more effective and potentially killing any cancer cells that may have already spread beyond the bladder but aren’t yet detectable.^[10]

For patients who cannot undergo surgery or prefer to avoid bladder removal, radiation therapy combined with chemotherapy offers an alternative. External beam radiation therapy uses a machine positioned outside the body to direct high-energy rays toward the bladder area, killing cancer cells or stopping their growth. When delivered alongside chemotherapy, this combination can be quite effective for certain patients with muscle-invasive disease.^[10]

The duration of treatment varies considerably depending on the type and extent of cancer. Intravesical BCG therapy typically follows a schedule where treatments are given once a week for six weeks, followed by maintenance therapy that continues for up to three years. This extended treatment period is necessary because of bladder cancer’s tendency to recur. Chemotherapy for advanced disease usually involves multiple cycles given over several months, with exact timing determined by how well the patient tolerates treatment and how the cancer responds.^[8]

Side effects are an important consideration with all bladder cancer treatments. Intravesical therapies commonly cause bladder irritation, leading to frequent and urgent urination, burning sensations, and sometimes blood in the urine. These symptoms usually resolve after treatment ends. Systemic chemotherapy—medication that travels throughout the entire body—can cause more widespread effects including fatigue, nausea, hair loss, increased infection risk due to low blood cell counts, and damage to organs like the kidneys or nerves. Radiation therapy may cause skin irritation in the treatment area, fatigue, and bladder inflammation that produces symptoms similar to a urinary tract infection.^[10]

Innovative Treatments in Clinical Trials

Clinical research has brought exciting advances to bladder cancer treatment, particularly in the realm of immunotherapy. Beyond the traditional BCG treatment, newer immunotherapy drugs work by targeting specific molecules that cancer cells use to hide from the immune system. Several drugs in a class called checkpoint inhibitors have been approved for advanced bladder cancer. These medications—atezolizumab (Tecentriq), and related drugs—target the PD-1 or PD-L1 pathway. Cancer cells often display PD-L1 proteins on their surface, which act like a “don’t attack me” signal to immune cells. Checkpoint inhibitors block this interaction, essentially removing the cancer’s disguise and allowing immune cells to recognize and destroy the tumor.^[13]

These immunotherapy drugs are approved for subsets of patients with advanced bladder cancer, particularly those whose tumors have specific characteristics or who haven’t responded to chemotherapy. Clinical trials are ongoing to test these medications in earlier stages of disease and in different combinations to see if they can benefit more patients.^[13]

A particularly promising development involves antibody-drug conjugates, which represent a sophisticated approach to targeting cancer cells. These treatments combine two elements: an antibody that recognizes a specific protein on cancer cells, and a toxic drug attached to that antibody. The antibody acts like a guided missile, delivering the toxic payload directly to cancer cells while sparing healthy tissue. Enfortumab vedotin (Padcev) targets a protein called Nectin-4 that’s commonly found on bladder cancer cells. Sacituzumab govitecan (Trodelvy) targets another protein called TROP-2. Both drugs have been approved for subsets of patients with advanced bladder cancer who have received prior treatments.^[13]

One of the most exciting recent advances involves a novel drug delivery system called TAR-200. This miniature, pretzel-shaped device contains the chemotherapy drug gemcitabine and is inserted into the bladder through a catheter. Unlike traditional intravesical chemotherapy that’s drained from the bladder after a few hours, TAR-200 stays in place and slowly releases medication over three weeks. This extended exposure allows the drug to penetrate more deeply into bladder tissue.^[9]

Results from a Phase 2 clinical trial called SunRISe-1 showed remarkable effectiveness. The trial included 85 patients with high-risk non-muscle-invasive bladder cancer whose tumors had not responded to standard BCG treatment—a challenging group that previously had limited options besides bladder removal. In this study, TAR-200 eliminated tumors in 82% of patients (70 out of 85). In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patients remained cancer-free a year later. The treatment was generally well-tolerated with minimal side effects.^[9]

The trial was conducted at 144 locations globally, including sites in the United States, Europe, and other regions. Patients enrolled had to meet specific eligibility criteria related to their cancer stage, previous treatments, and overall health status. While the main trial is closed to new participants, other studies investigating TAR-200 in different patient populations are ongoing.^[9]

Clinical trials are structured in phases to systematically evaluate new treatments. Phase I trials focus primarily on safety—determining the right dose and identifying potential side effects in a small group of participants. Phase II trials, like the SunRISe-1 study, expand to a larger group to assess whether the treatment is effective and to gather more safety information. Phase III trials involve even more patients and compare the new treatment directly against the current standard of care to determine if it offers superior benefits. This phased approach ensures that by the time a treatment reaches widespread use, extensive data supports its safety and effectiveness.^[4]

Gene therapy and other cutting-edge approaches are also being explored in preclinical and early clinical studies. These experimental strategies aim to modify cancer cells’ genetic material or leverage the body’s own cellular machinery in new ways to fight disease. While these approaches are not yet ready for routine use, they represent the frontier of bladder cancer research and hold promise for future treatment options.^[10]

Most common treatment methods

• Surgery
  • Transurethral resection (TUR) with fulguration removes tumors through the urethra using a cystoscope and wire loop
  • Partial cystectomy removes part of the bladder for tumors limited to one area
  • Radical cystectomy completely removes the bladder and nearby organs, followed by urinary diversion to create a new way to store and pass urine
• Intravesical therapy
  • BCG (Bacillus Calmette-Guérin) immunotherapy uses weakened bacteria delivered directly into the bladder to stimulate immune response
  • Intravesical chemotherapy, such as mitomycin C, delivers cancer-killing drugs directly into the bladder
  • TAR-200 is a drug-releasing device that stays in the bladder for three weeks, continuously delivering gemcitabine chemotherapy
• Systemic chemotherapy
  • Cisplatin-based combinations, such as gemcitabine plus cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
  • Often given before bladder removal surgery (neoadjuvant) or for recurrent and advanced disease
• Radiation therapy
  • External beam radiation therapy directs high-energy rays at the bladder from outside the body
  • Often combined with chemotherapy for patients who cannot undergo or prefer to avoid surgery
• Immunotherapy
  • Checkpoint inhibitors like atezolizumab (Tecentriq) block PD-1/PD-L1 pathways to help immune cells attack cancer
  • Approved for subsets of patients with advanced bladder cancer
• Targeted therapy
  • Enfortumab vedotin (Padcev) is an antibody-drug conjugate targeting Nectin-4 protein on cancer cells
  • Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate targeting TROP-2 protein
  • Both approved for subsets of patients with advanced bladder cancer after prior treatments